iOnctura bolsters executive team as it advances Phase II cancer trials

Swiss biotech iOnctura has appointed Steven Sciuto as chief financial officer and Michelle Tsai as chief operating officer, marking a leadership shift as the company moves deeper into Phase II trials for its lead cancer candidate, roginolisib (IOA-244).

The Geneva-based company, which is also registered in Amsterdam, is building momentum behind its clinical strategy targeting rare and hard-to-treat cancers. The two new hires bring significant financial and commercial expertise to iOnctura’s senior team at a time when the company is navigating a critical growth phase.

Mr Sciuto joins from US biotech Neurogene, where he most recently served as vice president of finance. He has more than 15 years of experience in the life sciences sector, and has helped secure more than $400 million in funding across private and public markets.